Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Tapeworm drug targets common vulnerability in tumor cells

Tapeworm drug targets common vulnerability in tumor cells

gene
Credit: CC0 Public Domain

A drug used to treat tapeworm infections could also be used to fight a wide range of cancers, an A*STAR study suggests.

More than half of human cancers carry a mutation in the tumor suppressor gene p53, making it an attractive target for cancer therapy. Many research efforts have focused on directly or indirectly restoring p53 function in mutated cells, but the team, led by Chit Fang Cheok of A*STAR’s Institute of Molecular and Cell Biology, took a different approach. Instead of trying to fix p53, which mutates in hundreds of ways in cancers, they exploited the differences between wild-type and p53-deficient cells to develop a treatment based on the vulnerabilities of p53-deficient cancer cells, “targeting the loss of function, the absence of p53,” Cheok says.

The team tested the effect of 1,600 FDA-approved compounds on cultured colon cancer cells with normal and mutated versions of p53. The compound that was best at killing p53-deficient cells, rather than cells with p53, was niclosamide, a drug used to treat tapeworm infections. Subsequent tests showed that niclosamide was also effective against other p53-deficient cancer cell lines.

Niclosamide is known to affect cells by interfering with energy production in mitochondria (an effect known as ‘mitochondrial uncoupling’) and causing changes in fatty acid metabolism. Experiments showed that mitochondrial uncoupling is integral to niclosamide’s ability to selectively kill p53-deficient cells, but isn’t enough to explain it, since a similar amount of uncoupling was also seen in p53-positive cells. In other words, it was still unclear why the drug was more effective against p53-deficient cells. “We went on a long ‘Sherlock Holmes’-like journey to understand what was happening,” says Cheok.

They examined the metabolic profile of niclosamide-treated cells and found that the p53-deficient cells had significantly more of a fatty acid known as arachidonic acid. Their investigation revealed that the mitochondrial uncoupling caused by niclosamide increases the calcium concentration in a cell, which boosts the production of arachidonic acid.

The team showed that this increase is normally counteracted by p53, which switches on two genes that break down arachidonic acid, ALOX5 and ALOX12B. These genes were not activated in p53-deficient cells, allowing arachidonic acid to accumulate, and causing mitochondria to release a molecule known as cytochrome c, leading to programmed cell death. Future work may identify other drugs that activate the same pathway and could also be used to treat p53-deficient cancers. “We were able to join all these dots in a very surprising manner, which was very exciting,” says Cheok.

To confirm their model, the researchers knocked out ALOX5 and ALOX12B in cells with a working copy of p53. They found that the engineered cells were more sensitive to niclosamide treatment even though they had a functioning p53 gene. Likewise, knocking out ALOX5 and ALOX12B in p53-deficient cells did not increase their niclosamide sensitivity.

Finally, the team confirmed that niclosamide is effective against p53-deficient cancers in animals, and not only in cultured cells. They injected mice with cells from the colon cancer cultures and measured tumor progress following niclosamide treatment. Niclosamide reduced tumor growth by 50 per cent in mice which had received p53-deficient cells but had no effect on tumors in mice injected with p53-positive cells.

Based on their findings, the researchers have filed a patent for the use of niclosamide to treat p53-deficient cancers. Since this approach targets deficiency rather than a specific mutation, Cheok expects it to be effective against a broad spectrum of cancers. Niclosamide has been used to treat humans for decades and is listed by the WHO as an effective, safe, and cheap medicine, raising hope for its use a potent, safe therapy against a broad spectrum of cancers with non-functional p53.


Tapeworm drug could lead the fight against Parkinson’s disease


More information:
R. Kumar et al. Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers, Nature Communications (2018). DOI: 10.1038/s41467-018-05805-1


Provided by
Agency for Science, Technology and Research (A*STAR), Singapore

Citation:
Tapeworm drug targets common vulnerability in tumor cells (2019, March 18)
retrieved 21 March 2019
from https://medicalxpress.com/news/2019-03-tapeworm-drug-common-vulnerability-tumor.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

Tagged with:

About author

Related Articles